Australian Institute for
Infectious Disease
Infectious Disease
Foundation Partners
Major Supporting Partner
The Australian Institute for Infectious Disease (AIID) will be a collaboration involving world-leading medical research and public health organisations in Victoria. Allowing for access to state-of-the-art infrastructure and technologies to further enhance our capacity to protect Australia and the region against infectious diseases and future pandemics.
Infectious diseases will continue to be a threat for Australia and the world. Learning from COVID-19, we can strengthen our capability to respond and protect the community. The AIID will do this by unifying our efforts, providing access to the right research infrastructure and knowledge networks, and increasing engagement with industry.
Victoria’s medical, scientific and research community has played a key role during the COVID-19 pandemic, in scientific discovery, vaccine development, therapeutics, diagnostics and modelling that had global impact.
The AIID will further establish Victoria as a global leader in infectious diseases and public health. The initiative will harness the immense potential of Victoria’s biomedical sector, providing opportunities for research collaboration, platform and knowledge-sharing.
The AIID will support the translation of ground-breaking research into life-saving outcomes, including the development of therapeutics, diagnostics, and vaccines.
In addition to delivering significant research and public health outcomes, the AIID will also support hundreds of jobs, increasing productivity of the biomedical sector and driving commercialisation opportunities.
The AIID has provided an expert submission as part of a comprehensive consultation process led by the Federal Government to guide its contribution to reforming the International Health Regulations (IHR) and the formulation of a new international pandemic accord. The AIID called for improved international rules for surveillance, early detection and responses to new and emerging diseases in order to avoid a repeat of the inequitable and disjointed outcomes seen during the emergency phase of the COVID-19 pandemic. Read the full submission here.